Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch

Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year.

Moderna beats loss estimates, revenue expectations

In the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.07 per share, which was less than the anticipated loss of $3.56 per share according to FactSet consensus.

This marks a significant shift from the net income of $79 million, or 19 cents per share, reported in the same period last year.

Despite the steep year-over-year decline, the company’s revenues of $167 million in the quarter still surpassed the FactSet consensus of $93 million by a considerable margin.

Anticipation builds for RSV vaccine approval

Moderna has reiterated its full-year 2024 guidance, projecting $4 billion in product sales.

This forecast includes revenues from its COVID-19 vaccine and a new respiratory syncytial virus (RSV) vaccine.

The company is optimistic about launching the RSV vaccine in time for the upcoming fall vaccination season.

A decision from the Food and Drug Administration (FDA) on the RSV vaccine is expected by May 12, setting the stage for a crucial recommendation from the Centers for Disease Control and Prevention’s advisory committee on immunization practices in late June.

Competing in a crowded market

The new RSV vaccine from Moderna is set to enter a competitive market, with established products from giants like GSK PLC and Pfizer Inc. already available.

However, the company’s advancements and the strategic timing of the launch could position it favorably within this space.

Synchronized vaccine rollouts planned

Looking ahead to the fall, Moderna is coordinating with the FDA and other regulators to align the timing for updated flu and COVID vaccine approvals.

The company aims for an earlier, synchronized release of these vaccines to potentially increase overall vaccine uptake during the seasonal vaccination periods.

Leveraging AI for operational efficiency

Moderna is also enhancing its operational efficiency through the use of artificial intelligence.

CEO Stephane Bancel highlighted the company’s ongoing efforts to integrate AI into its operations, including a recent expansion in its collaboration with OpenAI.

This move is expected to bolster productivity and streamline various processes within the company as it prepares for new vaccine rollouts.

Overall, despite its first-quarter losses, Moderna is positioning itself strongly for the remainder of the year with promising new products and innovative strategies aimed at improving its market presence and operational effectiveness.

The post Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch appeared first on Invezz